Jade Biosciences, Inc. 8-K

What Happened

• Jade Biosciences (JBIO) announced on June 25, 2026 that the Board appointed Mark Eisner, M.D., M.P.H., as a Class I director, to serve until the company’s 2028 annual meeting. Dr. Eisner was also named to the Board’s Nominating and Corporate Governance Committee. The company furnished a related press release on June 26, 2026 (Exhibit 99.1).

Key Details

• Appointment date: June 25, 2026; term through the 2028 annual meeting of stockholders.
• Compensation: eligible for the company’s standard non-employee director cash retainer and granted a stock option to purchase 47,675 shares under the 2025 Stock Incentive Plan.
• Vesting: the option vests in equal monthly installments over three years with full vesting upon a change in control (subject to continued service).
• Background: Dr. Eisner most recently served as EVP & Chief Medical Officer at Vir Biotechnology (June 2024–April 2026), and previously held senior roles at Sonoma Biotherapeutics, FibroGen (2020–Sept 2023), and Genentech (nearly 11 years). He holds an A.B. from Stanford, an M.D. from University of Pennsylvania, and an M.P.H. from UC Berkeley.
• Other: Dr. Eisner is expected to enter the company’s standard indemnification agreement and currently serves on the board of Zura Bio Ltd.

Why It Matters

• The appointment adds an experienced clinical development and regulatory executive to Jade’s board, based on Dr. Eisner’s recent CMO and senior product development roles at multiple biopharma companies. For investors, note the equity grant (47,675‑share option) which aligns his compensation with shareholder interests and the option’s change‑in‑control vesting provision. The filing is administrative (director appointment and related compensation) and does not report operational or financial results.